A novel advanced glycation index and its association with diabetes and microangiopathy

Rangasamy, Sampathkumar; Balasubramanyam, Muthuswamy; Mohan, Rema; Premanand, C.; Mohan, Viswanathan

doi:10.1016/j.metabol.2005.02.017

Cited by 48 publications

(21 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The serum levels of AGEs were higher in diabetic subjects without complications compared with nondiabetic subjects, higher among diabetic subjects with retinopathy and highest in diabetic subjects with both retinopathy and nephropathy in the study of Sampathkumar et al (2005). Sampathkumar et al (2005) found a signifi cantly positive correlation between AGEs and glycated hemoglobin, cholesterol and triacylglycerols.…”

Section: Discussionmentioning

confidence: 80%

Impact of glycemic control on advanced glycation and inflammation in overweight and obese patients with type 2 diabetes mellitus

Kalninova¹,

Jakuš²,

Glejtkova³

et al. 2014

BLL

View full text Add to dashboard Cite

Abstract:Aim: In this study we tried to investigate the impact of glycemic control on parameters of glycation and infl ammation in overweight and obese patients with type 2 diabetes mellitus. Patients and methods: Markers of glycation (HbA 1c , AGEs; measured by HPLC and spectrofl uorimetry, resp.) and infl ammatory markers (IL-6, IL-8, TNF-α, MCP-1; measured by xMAP technology) were assessed in 69 patients with T2DM, of whom 32 were patients were with poor glycemic control (PGC group), 37 patients were with good glycemic control (GGC group) and 23 were healthy blood volunteers. Results: Our results showed that plasma levels of fl uorescent AGEs, IL-6, IL-8, TNF-α, and MCP-1 were signifi cantly increased in PGC and GGC groups in comparison with control group, while the levels were higher in PGC group in comparison with GGC group, but the difference was not signifi cant. We found a positive correlation between AGEs and MCP-1 and between TNF-α and creatinine in PGC group. We found signifi cantly decreased levels of glycated HbA 1c and AGEs in patients who used statins compared to patients who used fi brates. We observed benefi cial impact of treatment with oral antidiabetic (OAD) agents + insulin on levels of IL-8, TNF-α and TAG in comparison with treatment with insulin alone. Conclusions: Despite good glycemic compensation of patients with T2DM, levels of AGEs and infl ammatory markers remained signifi cantly elevated in comparison with healthy controls. There was a benefi cial impact of treatment with OAD agents + insulin in sense of lowering the low-grade infl ammation (Tab. 3, Fig. 7, Ref. 113). Text in PDF www.elis.sk.

show abstract

Section: Discussionmentioning

confidence: 80%

Impact of glycemic control on advanced glycation and inflammation in overweight and obese patients with type 2 diabetes mellitus

Kalninova¹,

Jakuš²,

Glejtkova³

et al. 2014

BLL

View full text Add to dashboard Cite

show abstract

“…Serum level of AGEs was determined as described by Sampathkumar et al [26]. In brief, serum aliquot was diluted in phosphate-buffered saline (1∶50) and the fluorescence was determined (λ excitation = 370 nm, λ emission = 440 nm) using LS45 spectrofluorometer (PerkinElmer Inc., USA).…”

Section: Methodsmentioning

confidence: 99%

Ursodeoxycholic Acid Ameliorates Fructose-Induced Metabolic Syndrome in Rats

Mahmoud

Elshazly

2014

PLoS ONE

View full text Add to dashboard Cite

The metabolic syndrome (MS) is characterized by insulin resistance, dyslipidemia and hypertension. It is associated with increased risk of cardiovascular diseases and type-2 diabetes. Consumption of fructose is linked to increased prevalence of MS. Ursodeoxycholic acid (UDCA) is a steroid bile acid with antioxidant, anti-inflammatory activities and has been shown to improve insulin resistance. The current study aims to investigate the effect of UDCA (150 mg/kg) on MS induced in rats by fructose administration (10%) in drinking water for 12 weeks. The effects of UDCA were compared to fenofibrate (100 mg/kg), an agonist of PPAR-α receptors. Treatment with UDCA or fenofibrate started from the 6th week after fructose administration once daily. Fructose administration resulted in significant increase in body weight, elevations of blood glucose, serum insulin, cholesterol, triglycerides, advanced glycation end products (AGEs), uric acid levels, insulin resistance index and blood pressure compared to control rats. Moreover, fructose increased oxidative stress in aortic tissues indicated by significant increases of malondialdehyde (MDA), expression of iNOS and reduction of reduced glutathione (GSH) content. These disturbances were associated with decreased eNOS expression, increased infiltration of leukocytes and loss of aortic vascular elasticity. Treatment with UDCA successfully ameliorated the deleterious effects of fructose. The protective effect of UDCA could be attributed to its ability to decrease uric acid level, improve insulin resistance and diminish oxidative stress in vascular tissues. These results might support possible clinical application of UDCA in MS patients especially those present with liver diseases, taking into account its tolerability and safety. However, further investigations on human subjects are needed before the clinical application of UDCA for this indication.

show abstract

“…A first group of methods makes use of the ability of several AGEs to generate fluorescence at specific wavelengths (excitation 370 nm/emission 440 nm) (46 ). Using the same properties, a noninvasive method has been developed for assessing accumulation of AGEs in dermal proteins by measuring skin autofluorescence with a dedicated device.…”

Section: Advanced Glycation End Productsmentioning

confidence: 99%

Evaluation of Nonenzymatic Posttranslational Modification–Derived Products as Biomarkers of Molecular Aging of Proteins

2010

View full text Add to dashboard Cite

BACKGROUND During their biological life, proteins are exposed in a cumulative fashion to irreversible nonenzymatic, late posttranslational modifications that are responsible for their molecular aging. It is now well established that these damaged proteins constitute a molecular substratum for many dysfunctions described in metabolic and age-related diseases, such as diabetes mellitus, renal insufficiency, atherosclerosis, or neurodegenerative diseases. Accordingly, the specific end products derived from these reactions are considered potentially useful biomarkers for these diseases. CONTENT The aim of this review is to give an overview of nonenzymatic posttranslational modifications of proteins and their influence in vivo, take inventory of the analytical methods available for the measurement of posttranslational modification–derived products, and assess the potential contribution of new technologies for their clinical use as biological markers of protein molecular aging. SUMMARY Despite their clinical relevance, biomarkers of posttranslational modifications of proteins have been studied only in the context of experimental clinical research, owing to the analytical complexity of their measurement. The recent implementation in clinical chemistry laboratories of mass spectrometry–based methods that provide higher specificity and sensitivity has facilitated the measurement of these compounds. These markers are not used currently by clinicians in routine practice, however, and many challenges, such as standardization, have to be confronted before these markers can be used as efficient tools in the detection and monitoring of long-term complications of metabolic and age-related diseases.

show abstract

A novel advanced glycation index and its association with diabetes and microangiopathy

Cited by 48 publications

References 38 publications

Impact of glycemic control on advanced glycation and inflammation in overweight and obese patients with type 2 diabetes mellitus

Impact of glycemic control on advanced glycation and inflammation in overweight and obese patients with type 2 diabetes mellitus

Ursodeoxycholic Acid Ameliorates Fructose-Induced Metabolic Syndrome in Rats

Evaluation of Nonenzymatic Posttranslational Modification–Derived Products as Biomarkers of Molecular Aging of Proteins

Contact Info

Product

Resources

About